Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Inhibitor for immune cell migration

An immune cell and inhibitor technology, which can be used in anti-inflammatory agents, non-central analgesics, medical preparations containing active ingredients, etc., and can solve problems such as skin side effects

Active Publication Date: 2019-05-07
VIVA VISION SHANGHAI LTD
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Internationally, there are only a few options for dry eye patients (cyclosporine, Lifitegrast, etc.), but there is no topical drug approved for the treatment of dry eye disease in China, and the main topical drugs for psoriasis and eczema are steroids and cyclosporin etc., have a strong side effect on the skin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Inhibitor for immune cell migration
  • Inhibitor for immune cell migration
  • Inhibitor for immune cell migration

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0117]

[0118] (S)-2-(8-Chloro-2-(benzofuran-6-carbonyl)-2,3-dihydro-1H-pyrrole[3,2,1-ij]quinazoline-7-carboxamide base)-3-(3-(methylsulfonyl)phenyl)propionic acid

[0119] The specific reaction equation is as follows:

[0120]

[0121] Step A: Dimethyl 2-amino-5-chloroterephthalate (Compound 1-1)

[0122]To a vigorously stirred solution of dimethyl 2-aminoterephthalate (10 g, 48 mmol) in isopropanol (1.5 L) was added NCS (7.34 g, 55 mmol) over a period of 5 minutes at room temperature. After the addition was complete, the reaction mixture was heated to reflux for 48 hours. After cooling to room temperature, the solvent was concentrated and the residue was purified by flash chromatography eluting with 5% ethyl acetate in petroleum jelly to give the desired product (6.4 g, 55%) as a pale yellow crystalline solid. LCMS ESI (+) m / z: 244 (M+1). 1 H NMR (600MHz, CDCl3) δ7.92(s,1H),7.10(s,1H),5.71(brs,2H),3.92(s,3H),3.90(s,3H).

[0123] Step B: Dimethyl 2-amino-3-bromo-5...

Embodiment 2

[0150]

[0151] (S)-2-(8-Chloro-2-(1H-indole-6-carbonyl)-2,3-dihydro-1H-pyrrole[3,2,1-ij]quinazoline-7- Formamido)-3-(3-(methylsulfonyl)phenyl)propanoic acid

[0152] The title compound was prepared according to the procedure of Example 1, Steps M and N, using 1H-indole-6-carboxylic acid instead of compound benzofuran-6-carboxylic acid to give a white solid. LCMS ESI (+) m / z: 605 (M+1). 1 H NMR(600MHz,DMSO)δ12.89(brs,1H),11.39(s,1H),8.78(d,J=8.2Hz,1H),7.89(s,1H),7.79(d,J=7.8Hz ,1H),7.70(d,J=7.5Hz,1H),7.63(d,J=8.1Hz,1H),7.59(t,J=7.7Hz,1H),7.52(s,1H),7.53–7.46 (m,1H),7.46(s,1H),7.04(d,J=8.2Hz,1H),7.03–6.93(m,1H),6.52(s,1H),6.13(s,1H),5.99– 5.78(m,2H),5.14–4.95(m,2H),4.85–4.69(m,1H),3.30–3.26(m,1H),3.12(s,3H),3.10–3.03(m,1H).

Embodiment 3

[0154]

[0155] (S)-2-(8-chloro-2-(pyrazol[1,5-a]pyridine-2-carbonyl)-2,3-dihydro-1H-pyrrole[3,2,1-ij] Quinazoline-7-carboxamido)-3-(3-(methylsulfonyl)phenyl)propionic acid

[0156] The title compound was prepared according to the method of Steps M and N of Example 1, using pyrazol[1,5-a]pyridine-2-carboxylic acid instead of compound benzofuran-6-carboxylic acid to obtain a white solid. LCMS ESI (+) m / z: 606 (M+1). 1 H NMR (600MHz, DMSO) δ12.89(brs, 1H), 8.76(d, J=8.0Hz, 1H), 8.75(d, J=6.5Hz, 1H), 7.88(s, 1H), 7.79(d ,J=8.3Hz,1H),7.77(d,J=10.1Hz,1H),7.69(d,J=7.6Hz,1H),7.58(t,J=7.7Hz,1H),7.63–7.40(m ,1H),7.33(t,J=7.7Hz,1H),7.10–7.01(m,1H),7.15–6.92(m,1H),6.90(s,1H),6.30–6.18(m,1H), 6.17–6.06(m,1H),,6.06–5.93(m,1H),5.44–5.31(m,1H),5.23–5.08(m,1H),4.82–4.74(m,1H),3.32(dd, J=14.3,4.3Hz,1H),3.11(s,3H),3.05(dd,J=13.5,11.4Hz,1H).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses an inhibitor for immune cell migration. The inhibitor has the characteristic of a structure as shown in a following formula. The inhibitor has balanced hydrophilicity and lipotropy, can be developed into eyedrops easily and external applied plaster, has a high inhibitory effect on immune cell migration, and can alleviate most dry eye diseases and eczematous dermatitis and psoriasis.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to an immune cell migration inhibitor. Background technique [0002] Many local diseases are related to inflammation, such as irritant contact dermatitis, eczematous dermatitis, seborrheic dermatitis, scar formation, atopic dermatitis, psoriasis, etc. in skin care diseases; Immune disorders such as intraocular inflammation, periocular inflammation, ocular surface inflammation, keratoconjunctivitis, keratoconjunctivitis sicca (KCS, also known as dry eye), KCS in patients with Sjogren syndrome, allergic conjunctivitis, uvea Inflammation of the eye, inflammation of the eye caused by wearing a contact lens, inflammation of the cornea caused by wearing a contact lens, inflammation of the tissues around the eye caused by wearing a contact lens, inflammation of the eye after surgery, inflammation of the eye, retinitis, edema, retinopathy, inflammation of the cornea , Graves' disease (Basedow's dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C07D487/06C07D519/00C07D209/08C07D405/12A61K31/519A61K31/404A61K31/551A61P29/00A61P27/04A61P17/08A61P17/00A61P27/02
CPCA61K31/404A61K31/519A61K31/551A61P17/00A61P17/08A61P27/02A61P27/04A61P29/00C07D209/08C07D405/12C07D487/04C07D487/06C07D519/00Y02P20/55
Inventor 沈旺丁悦汪江峰姜浩陈福利吴兴龙李寸飞杨立国胡彪
Owner VIVA VISION SHANGHAI LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com